Weight-loss drug developer Metsera reveals wider loss in US IPO filing
(Reuters) -Weight-loss drug developer Metsera, backed by ARCH Venture Partners, revealed a wider loss in its paperwork for a ...
Metsera Files for IPO
Metsera has filed for an initial public offering. The clinical-stage biopharmaceutical company submitted a registration statement to regulators on Friday, saying it intends to list under the ticker ...
US proposes payment rate for 2026 Medicare Advantage insurers
The U.S. government on Friday proposed 2026 reimbursement rates for Medicare Advantage plans run by private insurers that ...
ENDPOINTS NEWS13h
Break­ing: Chas­ing the next wave of obe­si­ty drugs, Met­sera files for an IPO
Metsera files for IPO, developing GLP-1 drug MET-097i and other obesity treatments to compete with Eli Lilly and Novo Nordisk ...
U.S. IPO Weekly Recap: Flowco Launches First Major IPO Of 2025 As Smithfield, Others Join The Pipeline
Energy equipment and services provider Flowco launched the year’s first major IPO, planning to raise $392 million and list in ...
The Next Web20h
Verdiva launches with $410M for weight loss drugs to challenge Ozempic, Wegovy
The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.
Trump to inherit a strong economy from Biden, and what else?
President-elect Donald Trump is a week and a half away from inheriting a strong economy from President Joe Biden. Yahoo ...
The New York Times12h
New York Times - Top Stories
Supreme Court Seems Poised to Uphold Law That Could Ban TikTok The justices are expected to rule quickly in the case, which pits national security concerns about China against free speech ...